Navigation Links
Feinstein Institute researchers identify brain network
Date:7/18/2014

Manhassett, NY Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.

Parkinson's disease is the second most common neurodegenerative disease in the US. Those who suffer from Parkinson's disease most often experience tremors, slowness of movement (bradykinesia), rigidity, and impaired balance and coordination. Patients may have difficulty walking, talking or completing simple daily tasks. They may also experience depression and difficulty sleeping due to the disease. The current standard for diagnosis of Parkinson's disease relies on a skilled healthcare professional, usually an experienced neurologist, to determine through clinical examination that someone has it. There currently is no cure for Parkinson's disease, but medications can improve symptoms.

A team of researchers at the Feinstein Institute's Center for Neurosciences, led by David Eidelberg, MD, has developed a method to identify brain patterns that are abnormal or indicate disease using imaging techniques. To date, this approach has been used successfully to identify specific networks in the brain that indicate a patient has or is at risk for Parkinson's disease and other neurodegenerative disorders.

"One of the major challenges in developing new treatments for neurodegenerative disorders such as Parkinson's disease is that it is common for patients participating in clinical trials to experience a placebo or sham effect," noted Dr. Eidelberg. "When patients involved in a clinical trial commonly experience benefits from placebo, it's difficult for researchers to identify if the treatment being studied is effective. In a new study conducted by my colleagues and myself, we have used a new image-based strategy to identify and measure placebo effects in brain disorder clinical trials."

In the current study, the researchers used their network mapping technique to identify specific brain circuits underlying the response to sham surgery in Parkinson's disease patients participating in a gene therapy trial. The expression of this network measured under blinded conditions correlated with the sham subjects' clinical outcome; the network changes were reversed when the subjects learned of their sham treatment status. Finally, an individual subject's network expression value measured before the treatment predicted his/her subsequent blinded response to sham treatment. This suggests that this novel image-based measure of the sham-related network can help to reduce the number of subjects assigned to sham treatment in randomized clinical trials for brain disorders by excluding those subjects who are more likely to display placebo effects under blinded conditions.


'/>"/>
Contact: Emily Ng
eng3@nshs.edu
516-562-2670
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Feinstein Institute to receive grant to improve schizophrenia treatment
2. Feinstein Institute to Receive Grant from Centers for Medicare & Medicaid Services to Improve Schizophrenia Treatment
3. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
4. Feinstein announces submission of new drug application for diagnosing parkinsonian syndromes
5. Feinstein Institute researchers discover plant derivative
6. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
7. Feinstein Institute Scientist Wins Crafoord Award from Royal Swedish Academy of Sciences for Arthritis Research
8. Feinstein Institute Researcher provides insight into osteoarthritis
9. North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week
10. North Shore-LIJ's Feinstein Institute Hosts Academic Commencement and Convocation
11. Feinstein Institute, Hofstra North Shore-LIJ School of Medicine at 36th Annual Conference on Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed ... part of Saint Luke’s Health System . Dr. Upadhyaya has served in the ... FAANS joins Stanley P. Fisher, M.D., who has served as medical co-director ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire ... site and threatened numerous homes and businesses nearby, causing some 700 individuals to ... Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the report ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... 24, 2017 , ... The Magic Wand® Rechargeable, the top-of-the-line ... favorite sex toy. Created in collaboration with website Kinkly.com, the award was the ... The Magic Wand Rechargeable won in stiff competition from brands such as Lelo, ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology: